Levofloxacine Stada

Levofloxacin, the active ingredient in Levofloxacine Stada, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It targets a variety of Gram‑negative and Gram‑positive bacteria and is indicated for the treatment of community‑acquired pneumonia, urinary tract infections, sinusitis, bronchitis exacerbations, and skin infections in adult and adolescent patients.

GNH USA supplies Levofloxacine Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Levofloxacine Stada is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory, urinary and skin systems.

- Community‑acquired pneumonia: eradicates the causative bacteria, leading to clinical improvement and resolution of infection. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms. - Uncomplicated urinary tract infection: clears the urinary tract of susceptible pathogens, relieving symptoms. - Complicated urinary tract infection: provides bactericidal activity against resistant strains in upper urinary tract infections. - Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth, decreasing cough and sputum production. - Skin and soft‑tissue infections: treats cellulitis and other dermal infections caused by susceptible bacteria.

Levofloxacine Stada may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that usually resolves without intervention. - Diarrhea: loose stools that may be self‑limiting but should be monitored for dehydration. - Headache: transient cranial discomfort often improving with rest.

Serious or Rare Side Effects: - Tendon rupture: sudden pain and loss of function, most often in the Achilles tendon. - QT interval prolongation: may lead to cardiac arrhythmias, especially in patients with pre‑existing heart conditions. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea and abdominal cramping.

Before prescribing Levofloxacine Stada, clinicians should consider several safety precautions to minimize risk. - Assess renal function: dose adjustment may be required in patients with impaired clearance. - Avoid in patients with a history of tendon disorders: fluoroquinolones can precipitate tendon inflammation or rupture. - Use with caution in individuals with prolonged QT interval: monitor cardiac rhythm and avoid concurrent QT‑prolonging drugs. - Monitor for hypersensitivity reactions: discontinue if rash, angioedema or anaphylaxis occurs. - Limit concomitant use of non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use may increase risk of central nervous system effects. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Levofloxacine Stada can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: chelate the drug and markedly reduce oral absorption. - Warfarin: potentiates anticoagulant effect, increasing risk of bleeding. - Theophylline: inhibits metabolism, leading to elevated plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely): - Ciprofloxacin or other fluoroquinolones: additive QT prolongation risk. - NSAIDs: may enhance central nervous system stimulation and seizure propensity. - Cyclosporine: levofloxacin can increase cyclosporine levels, requiring therapeutic drug monitoring.